All studies
Cardiology · Claims · US

Stephan 2026

Heart failure with preserved ejection fraction

QBA performedPPSuperiorityAcademia4/5 disclosures
Comparisons
4
In the analysis
0
4 withheld
Target trials
1
Emulations reported
1
2 treatments

Comparisons

4 shown
Randomized trialEmulation
Outcome & target trialTrial vs emulationOn a shared scaleAgreement
All-cause mortality
vs TOPCAT·RR·Efficacy
1.141.11–1.18
not pooledClose alignment
Cardiovascular mortality
vs TOPCAT·RR·Efficacy
1.081.01–1.16
not pooledClose alignment
Heart-failure hospitalization
vs TOPCAT·RR·Efficacy
1.010.99–1.04
not pooledClose alignment
Heart-failure hospitalization, cardiac arrest, or cardiovascular death
vs TOPCAT·RR·Efficacy
0.970.94–1.01
not pooledClose alignment

Design and methods

Estimand
PP
Design hypothesis
Superiority
Matching / weighting
Clone-censor-weight
Analysis method
IPCW pooled survival model
Missing data
Complete case
Covariates adjusted
143
DAG
No
QBA
Yes

Data and sample

Data type
Claims
Data sources
1
Geography
US
Eligible sample
320881
Treated
Cloned strategy arm
Control
Cloned strategy arm
Emulations
1
Treatments compared
2

Transparency

4/5
Protocol
https://doi.org/10.17605/OSF.IO/6MNCF
Preprint
No preprint
Data availability
Unavailable
Code availability
https://osf.io/4rqbd
Conflicts of interest
Declared: Industry
COI institutions
Vertex; Boehringer Ingelheim; Aetion; other relationships reported in the manuscript
Funding
Declared: Public, Research institute
Funders
Deutsche Forschungsgemeinschaft project 532417373; internal Brigham and Harvard funding

The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.

Provenance

Review key
2026_Stephan_TOPCAT
DOI
https://doi.org/10.1038/s43856-026-01796-z
Affiliations
Brigham and Women's Hospital; Harvard Medical School
Sector
Academia
Target trials (study level)
TOPCAT
Registration
NCT00094302